Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Zhuoyin Wang, Xinming Li, Jili Hu, Xu Guo, Bulang Gao, Bin Zhu
Numerous studies related to esophagogastric junction cancer (EGC) have been published, and bibliometric analysis of these publications may be able to identify research hotspots and frontiers of EGC. Studies published on EGC between 2002 and 2021 were retrieved from the Web of Science Core Collection. The collaboration network of countries/regions, institutions, authors, co-citation network of journals, co-occurrence network, and overlay visualization of keywords were analyzed using the VOSviewer software. Cluster and timeline analyses of references were performed using the CiteSpace software...
May 17, 2024: Medicine (Baltimore)
#2
REVIEW
Yue Zhang, Jingwen Chu, Qi Hou, Siyu Qian, Zeyuan Wang, Qing Yang, Wenting Song, Ling Dong, Zhuangzhuang Shi, Yuyang Gao, Miaomiao Meng, Mingzhi Zhang, Xudong Zhang, Qingjiang Chen
Cellular senescence has a complex role in lymphocyte carcinogenesis and drug resistance of lymphomas. Senescent lymphoma cells combine with immunocytes to create an ageing environment that can be reprogrammed with a senescence‑associated secretory phenotype, which gradually promotes therapeutic resistance. Certain signalling pathways, such as the NF‑κB, Wnt and PI3K/AKT/mTOR pathways, regulate the tumour ageing microenvironment and induce the proliferation and progression of lymphoma cells...
June 2024: International Journal of Oncology
#3
REVIEW
Rui-Jia Liu, Xu-Dong Yu, Shao-Shuai Yan, Zi-Wei Guo, Xiao-Bin Zao, Yao-Sheng Zhang
Hepatocellular carcinoma (HCC), one of the leading causes of cancer‑related mortality worldwide, is challenging to identify in its early stages and prone to metastasis, and the prognosis of patients with this disease is poor. Treatment options for HCC are limited, with even radical treatments being associated with a risk of recurrence or transformation in the short term. Furthermore, the multi‑tyrosine kinase inhibitors approved for first‑line therapy have marked drawbacks, including drug resistance and side effects...
June 2024: International Journal of Oncology
#4
JOURNAL ARTICLE
Sreekanth Reddy Obireddy, Wing-Fu Lai
PURPOSE OF REVIEW: The purpose of this review is to explore new strategies to treat bladder cancer. This article addresses challenges and opportunities in intravesical therapy of bladder cancer. RECENT FINDINGS: The review examines the latest advances in the development of preclinical approaches for intravesical therapy of bladder cancer. It discusses strategies to improve drug delivery efficiency by using synthesized diverse carriers. Immunotherapy with protein aggregate magnesium-ammonium phospholinoleate-palmitoleate anhydride has been shown to be more effective than intravesical Bacillus Calmette-Guerin...
May 17, 2024: Current Opinion in Urology
#5
Zheming Bao, Xiuchun Yu, Kai Zheng, Kai Zhai, Haocheng Cui, Ming Xu
BACKGROUND: Pulmonary sarcomatoid carcinoma (PSC) is a rare subtype of non-small-cell lung cancer (NSCLC), which is resistant to chemotherapy and radiotherapy with a poor prognosis. PSC is highly malignant and is prone to recurrence even after surgery. The programmed death-ligand 1 (PD-L1) tumor cell proportion score (TPS) 5%, TERT and TP53 gene mutations were detected in this patient accompanied by multiple metastatic sites. The anlotinib is a novel multitarget tyrosine kinase inhibitor (TKI) that could be effective for advanced NSCLC and some sarcoma patients...
2024: Frontiers in Immunology
#6
REVIEW
Rui Zheng, Xiaobin Liu, Yufu Zhang, Yongxian Liu, Yaping Wang, Shutong Guo, Xiaoyan Jin, Jing Zhang, Yuehong Guan, Yusi Liu
Pancreatic cancer is a highly aggressive malignant tumor, that is becoming increasingly common in recent years. Despite advances in intensive treatment modalities including surgery, radiotherapy, biological therapy, and targeted therapy, the overall survival rate has not significantly improved in patients with pancreatic cancer. This may be attributed to the insidious onset, unknown pathophysiology, and poor prognosis of the disease. It is therefore essential to identify and develop more effective and safer treatments for pancreatic cancer...
2024: Frontiers in Immunology
#7
REVIEW
Caroline Linde, Yu-Ting Chien, Zhiqian Chen, Qingxin Mu
Breast cancer with triple-negative subtype (TNBC) presents significant challenges with limited treatment options and a poorer prognosis than others. While PD-1/PD-L1 checkpoint inhibitors have shown promise, their efficacy in TNBC remains constrained. In recent years, nanoparticle (NP) technologies offer a novel approach to enhance cancer therapy by optimizing the tumor microenvironment and augmenting chemo- and immunotherapy effects in various preclinical and clinical settings. This review discusses recent investigations in NP strategies for improving PD-1/PD-L1 blockade-based combination therapy for TNBC...
2024: Frontiers in Oncology
#8
REVIEW
Hirotaka Miyashita, Shumei Kato, David S Hong
Although KRAS G12C inhibitors have proven that KRAS is a "druggable" target of cancer, KRAS G12C inhibitor monotherapies have demonstrated limited clinical efficacy due to primary and acquired resistance mechanisms. Multiple combinations of KRAS G12C inhibitors with other targeted therapies, such as RTK, SHP2, and MEK inhibitors, have been investigated in clinical trials to overcome the resistance. They have demonstrated promising efficacy especially by combining KRAS G12C and EGFR inhibitors for KRAS G12C-mutated colorectal cancer...
2024: Frontiers in Oncology
#9
REVIEW
Kate E Foley, Donna M Wilcock
The targeting of amyloid-beta (Aβ) plaques therapeutically as one of the primary causes of Alzheimer's disease (AD) dementia has been an ongoing effort spanning decades. While some antibodies are extremely promising and have been moved out of clinical trials and into the clinic, most of these treatments show similar adverse effects in the form of cerebrovascular damage known as amyloid-related imaging abnormalities (ARIA). The two categories of ARIA are of major concern for patients, families, and prescribing physicians, with ARIA-E presenting as cerebral edema, and ARIA-H as cerebral hemorrhages (micro- and macro-)...
2024: Frontiers in Aging Neuroscience
#10
JOURNAL ARTICLE
Meng Wu, Ke Li, Yangying Liao, Lan Li, Xiao Xiao, Yongjian Chen, Junweichen Guo, Feng Hu, Jing Qu, Zheng Wang, Hao Feng
OBJECTIVES: Melanoma is highly malignant and heterogeneous. It is essential to develop a specific prognostic model for improving the patients' survival and treatment strategies. Recent studies have shown that ferroptosis results from the overproduction of lipid peroxidation and is an iron-dependent form of programmed cell death. Despite this, ferroptosis-related genes (FRGs) and their clinical significances remain unknown in malignant melanoma. This study aims to assess the role of FRGs in melanoma, with the goal of developing a novel prognostic model that provides new insights into personalized treatment and improvement of therapeutic outcomes for melanoma...
February 28, 2024: Zhong Nan da Xue Xue Bao. Yi Xue Ban, Journal of Central South University. Medical Sciences
#11
REVIEW
Xin Liu, Hui Shen, Lu Zhang, Wenhui Huang, Shuixing Zhang, Bin Zhang
Immunotherapy, particularly immune checkpoint inhibitors (ICIs), such as anti-programmed death 1/programmed death-ligand 1 (PD-1/PD-L1) therapy, has emerged as a pivotal treatment modality for solid tumors, including recurrent or metastatic nasopharyngeal carcinoma (R/M-NPC). Despite the advancements in the utilization of ICIs, there is still room for further improving patient outcomes. Another promising approach to immunotherapy for R/M-NPC involves adoptive cell therapy (ACT), which aims to stimulate systemic anti-tumor immunity...
May 16, 2024: NPJ Precision Oncology
#12
JOURNAL ARTICLE
Yunyan Du, Zhangjian Yang, Hao Shi, Zhihan Chen, Rong Chen, Fan Zhou, Xiaogang Peng, Tao Hong, Liping Jiang
Pancreatic cancer (PC) is among the deadliest malignancies, with an extremely poor diagnosis and prognosis. Gemcitabine (GEM) remains the first-line drug for treating PC; however, only a small percentage of patients benefit from current immunotherapies or targeted therapies. Resistance to GEM is prevalent and affects long-term survival. We found that ubiquitin-protein ligase E3 module N-recognition 5 (UBR5) is a therapeutic target against GEM resistance. UBR5 was markedly upregulated in clinical GEM-resistant PC samples and GEM-resistant PC cells...
May 16, 2024: Cell Death & Disease
#13
REVIEW
Ranran Su, Yingying Shao, Manru Huang, Donghui Liu, Haiyang Yu, Yuling Qiu
Maturing immunometabolic research empowers immune regulation novel approaches. Progressive metabolic adaptation of tumor cells permits a thriving tumor microenvironment (TME) in which immune cells always lose the initial killing capacity, which remains an unsolved dilemma even with the development of immune checkpoint therapies. In recent years, many studies on tumor immunometabolism have been reported. The development of immunometabolism may facilitate anti-tumor immunotherapy from the recurrent crosstalk between metabolism and immunity...
May 16, 2024: Cell Death Discovery
#14
JOURNAL ARTICLE
Juan Carlos López-Gil, Susana García-Silva, Laura Ruiz-Cañas, Diego Navarro, Adrián Palencia-Campos, Antonio Giráldez-Trujillo, Julie Earl, Jorge Dorado, Gonzalo Gómez-López, Ana Monfort-Vengut, Sonia Alcalá, Matthias M Gaida, Sandra García-Mulero, Pablo Cabezas-Sáinz, Sandra Batres-Ramos, Emma Barreto, Patricia Sánchez-Tomero, Mireia Vallespinós, Leah Ambler, Meng-Lay Lin, Alexandra Aicher, Ana García García de Paredes, Carolina de la Pinta, Alfonso Sanjuanbenito, Ignacio Ruz-Caracuel, Mercedes Rodríguez-Garrote, Carmen Guerra, Alfredo Carrato, Guillermo de Cárcer, Laura Sánchez, César Nombela-Arrieta, Elisa Espinet, Víctor Javier Sanchez-Arevalo Lobo, Christopher Heeschen, Bruno Sainz
OBJECTIVE: Pancreatic ductal adenocarcinoma (PDAC) has limited therapeutic options, particularly with immune checkpoint inhibitors. Highly chemoresistant 'stem-like' cells, known as cancer stem cells (CSCs), are implicated in PDAC aggressiveness. Thus, comprehending how this subset of cells evades the immune system is crucial for advancing novel therapies. DESIGN: We used the KPC mouse model ( LSL-KrasG12D/+ ; LSL-Trp53R172H/+ ; Pdx-1-Cre ) and primary tumour cell lines to investigate putative CSC populations...
May 16, 2024: Gut
#15
JOURNAL ARTICLE
Tessa Gargett, Nga T H Truong, Bryan Gardam, Wenbo Yu, Lisa M Ebert, Amy Johnson, Erica C F Yeo, Nicole L Wittwer, Gonzalo Tapia Rico, Jesikah Logan, Purany Sivaloganathan, Maria Collis, Andrew Ruszkiewicz, Michael P Brown
BACKGROUND: Chimeric antigen receptor (CAR) T cell therapies specific for the CD19 and B-cell maturation antigen have become an approved standard of care worldwide for relapsed and refractory B-cell malignancies. If CAR-T cell therapy for non-hematological malignancies is to achieve the same stage of clinical development, then iterative early-phase clinical testing can add value to the clinical development process for evaluating CAR-T cell products containing different CAR designs and manufactured under differing conditions...
May 15, 2024: Journal for Immunotherapy of Cancer
#16
REVIEW
Soumyadeep Chattopadhyay, Rudradeep Hazra, Arijit Mallick, Sakuntala Gayen, Souvik Roy
Oncolytic viruses (OVs) are increasingly recognized as potent tools in cancer therapy, effectively targeting and eradicating oncogenic conditions while sparing healthy cells. They enhance antitumor immunity by triggering various immune responses throughout the cancer cycle. Genetically engineered OVs swiftly destroy cancerous tissues and activate the immune system by releasing soluble antigens like danger signals and interferons. Their ability to stimulate both innate and adaptive immunity makes them particularly attractive in cancer immunotherapy...
May 14, 2024: Biochimica et Biophysica Acta. Reviews on Cancer
#17
JOURNAL ARTICLE
Alexander M Menzies, Serigne N Lo, Robyn P M Saw, Maria Gonzalez, Sydney Ch'ng, Omgo E Nieweg, Kerwin F Shannon, Peter M Ferguson, Jenny Lee, Louise Emmett, Rony Kapoor, Robert V Rawson, Jonathan R Stretch, John F Thompson, Andrew J Spillane, Helen Rizos, Richard A Scolyer, Georgina V Long
BACKGROUND: Neoadjuvant dabrafenib plus trametinib has a high pathological response rate and impressive short-term survival in patients with resectable stage III melanoma. We report five-year outcomes from the phase II NeoCombi trial. METHODS: NeoCombi (NCT01972347) was a single-arm, open-label, single-centre, phase II trial. Eligible patients were adults (aged ≥18) with histologically-confirmed, resectable, RECIST-measurable AJCC 7th ed. clinical stage IIIB-C BRAF V600E/K-mutant melanoma and Eastern Co-operative Oncology Group performance status ≤1...
May 14, 2024: Annals of Oncology: Official Journal of the European Society for Medical Oncology
#18
REVIEW
Tarik Demir, Carolyn Moloney, Devalingam Mahalingam
In the last decade, targeted therapies have shown rapid advancement in biliary tract cancer (BTC). Today, many targeted agents are available and under investigation for patients with BTC. More recently, immune checkpoint inhibitors (ICI) such as durvalumab and pembrolizumab in combination with gemcitabine plus cisplatin (gem/cis) have resulted in improved overall survival and progression-free survival in the first-line setting. However, the efficacy benefit of these novel therapeutics is often short-lived, with literature outlining concerns about both primary and secondary resistance to these agents...
May 14, 2024: Critical Reviews in Oncology/hematology
#19
REVIEW
S S Kirthiga Devi, Sidhartha Singh, Ramesh Joga, Sharvari Y Patil, Vakalapudi Meghana Devi, Sabnis Chetan Dushantrao, Falguni Dwivedi, Gautam Kumar, Deepak Kumar Jindal, Charan Singh, Isha Dhamija, Sandeep Kumar
Cancer treatment modalities and their progression is guided by the specifics of cancer, including its type and site of localization. Surgery, radiation, and chemotherapy are the most often used conventional treatments. Conversely, emerging treatment techniques include immunotherapy, hormone therapy, anti-angiogenic therapy, dendritic cell-based immunotherapy, and stem cell therapy. Immune checkpoint inhibitors' anticancer properties have drawn considerable attention in recent studies in the cancer research domain...
May 14, 2024: European Journal of Pharmaceutics and Biopharmaceutics
#20
JOURNAL ARTICLE
Benjamin Caulier, Sandy Joaquina, Pascal Gelebart, Tara Helén Dowling, Fatemeh Kaveh, Moritz Thomas, Luka Tandaric, Patrik Wernhoff, Niveditha Umesh Katyayini, Cara Wogsland, May Eriksen Gjerstad, Yngvar Fløisand, Gunnar Kvalheim, Carsten Marr, Sebastian Kobold, Jorrit M Enserink, Bjørn Tore Gjertsen, Emmet McCormack, Else Marit Inderberg, Sébastien Wälchli
Acute myeloid leukemia (AML) is characterized by the accumulation of immature myeloid cells in the bone marrow and the peripheral blood. Nearly half of the AML patients relapse after standard induction therapy, and new forms of therapy are urgently needed. Chimeric antigen receptor (CAR) T therapy has so far not been successful in AML due to lack of efficacy and safety. Indeed, the most attractive antigen targets are stem cell markers such as CD33 or CD123. We demonstrate that CD37, a mature B cell marker, is expressed in AML samples, and its presence correlates with the European LeukemiaNet (ELN) 2017 risk stratification...
May 8, 2024: Cell reports medicine
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
